Offstream
news

A trial of a plant-based COVID-19 vaccine conducted by GSK and Medicago shows an overall 71% efficacy against disease caused by the predominant SARS-CoV-2 variants of concern observed during most of 2021, and 75% efficacy specifically against disease caused by Delta. The study excludes the Omicron variant, which was not in circulation at the time of the clinical trials.
2021-12-7

The Health Ministry panel committee approve the usage of the single-dose monoclonal antibody-based treatment sotrovimab developed by GlaxoSmithKline and Vir Biotechnology to treat mild and moderately-ill COVID-19 patients.
2021-09-27

GlaxoSmithKline and Sanofi begins new clinical trial of their protein-based vaccine candidate and aim to reach the final testing stage in the second quarter after setback last year.
2021-02-22

GlaxoSmithKline and the German biotech firm CureVac sign an agreement worth 150 million euros ($180.7 million) to develop a vaccine to counter many variants of SARS-CoV-2. The vaccine, which is subject to regulatory approval, is expected to be introduced in 2022.
2021-02-3

Sanofi and GlaxoSmithKline announce that their COVID-19 vaccine candidate will not be ready until the end of 2021.
2020-12-11

GlaxoSmithKline and Sanofi announces that they will start vaccine trials.
2020-09-3

Pharmaceutical giant GlaxoSmithKline agrees to sell its thrombosis drug brands to Aspen Pharmacare.
2013-09-30

Some scientists express concern that an influenza vaccine marketed by GlaxoSmithKline called Pandemrix may be responsible for an increase in cases of narcolepsy in Europe.
2013-02-8

A report commissioned by the Irish Department of Health finds significant increase in narcolepsy among individuals given the GlaxoSmithKline developed swine flu vaccine Pandemrix compared to those who did not receive the vaccine.
2012-04-19

GlaxoSmithKline pleads guilty to intentionally manufacturing and distributing adulterated drugs, including Paxil, and will pay $750 million for committing the felony.
2010-10-26